The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Factors to consider when selecting patients with SCD for alloSCT
Elisabeth Dovern, MD, Amsterdam UMC, Amsterdam, Netherlands, briefly discusses factors to consider when selecting adult patients with sickle cell disease (SCD) for allogeneic stem cell transplantation (alloSCT). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
